Finasteride and Tamoxifen Interaction: Avoid | Peptide Database

Proviron is one of the most reliable compounds for improving sexual desire and drive. Its DHT activity directly stimulates libido pathways, while its SHBG-binding effect increases free testosterone availability. Effects are often noticeable within the first week of use. By increasing free testosterone and DHT activity, Proviron can improve erectile firmness and frequency. Particularly effective in men whose erectile issues are related to low free testosterone or elevated SHBG. At doses of 25-50 mg/day, Proviron has been used clinically to improve sperm count and motility in oligospermic men. At these low doses, HPT axis suppression is minimal. Higher doses may suppress spermatogenesis. Proviron is widely reported to produce a noticeable improvement in mood, confidence, and overall psychological well-being. This is attributed to increased free testosterone and direct androgenic activity in the central nervous system. Many users describe a calm, confident, and motivated mindset. In men with documented androgen deficiency, Proviron has been used to alleviate depressive symptoms, fatigue, and loss of motivation. Not a replacement for standard psychiatric treatment but can complement hormonal optimization. Proviron reduces water retention and gives a visibly harder, more defined appearance. It does not significantly build muscle mass on its own due to rapid inactivation in muscle tissue, but it enhances the aesthetic quality of existing musculature. By binding SHBG and freeing bound testosterone, Proviron effectively increases the anabolic signal from a given testosterone dose. This makes it a potent adjunct to any testosterone-based protocol for improving body composition outcomes. Proviron has one of the highest binding affinities for SHBG of any androgen. This displaces testosterone from SHBG, increasing free testosterone without increasing total testosterone dose. Particularly useful in men with elevated SHBG who present with low free testosterone despite adequate total testosterone levels. Proviron provides a mild anti-estrogenic effect through aromatase competition, which can reduce or eliminate the need for a dedicated aromatase inhibitor on moderate testosterone doses. It is not a replacement for an AI in heavily aromatizing protocols but can meaningfully reduce estrogen-related side effects in standard TRT.

Join others researching RU-58841 — share findings, ask questions, and learn from real experiences RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown. RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.